Information borrowing in phase II randomized dose-ranging clinical trials in oncology
Guillaume Mulier, Vincent Lévy, Lucie Biard · 2026
Read Information borrowing in phase II randomized dose-ranging clinical trials in oncology by Guillaume Mulier, Vincent Lévy, Lucie Biard (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13397689.txt.
Description
Guillaume Mulier and others compare information borrowing strategies in phase II oncology dose-ranging trials in a 2026 study. Stock phase I dose picking based on toxicity alone has led to poor approved doses, as with ibrutinib, whose lower doses later matched response rates.
Spurred by that case, the team adapted the Bayesian Optimal Phase II design to multiple doses and compared borrowing strategies for sharpening statistical power. Dose tuning is now urged in oncology, and borrowing across doses can sharpen dose picking without bigger trials. Trial designers gain a methods comparison for modern dose-ranging studies.
Catalog record
| CREATOR | Guillaume Mulier, Vincent Lévy, Lucie Biard |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 70 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |